Titre original:
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF)
Indication (pathologie):
Heart failure
Identifiant SNOMED-CT:
84114007
Indication (pathologie):
Heart failure with reduced ejection fraction
Identifiant SNOMED-CT:
703272007
Identifiant EUDRA-CT:
2016-002280-34
Phase de l'étude:
Phase III
Recrutement:
Ouvert
Service:
Investigateur principal:
Van de Borne Philippe
Sponsor:
Boehringer Ingelheim Internation GmbH
Tél contact:
02 555 3907
Email contact:
Adresse hôpital:
Cliniques Universitaires de Bruxelles Hôpital Erasme
Route de Lennik 808,1070 Bruxelles, Belgique